RecruitingNot ApplicableNCT06708572

Evaluation of the Use of Granulocyte Colony Stimulating Factor (GCSF) in Post Kasai Type 3 Biliary Atresia

Sponsor

National Liver Institute, Egypt

Enrollment

40 participants

Start Date

Dec 1, 2024

Study Type

INTERVENTIONAL

Conditions

Biliary Atresia Granulocyte Colony-stimulating Factor

Summary

The aim of the study is to evaluate the use of Granulocyte Colony Stimulating Factor (GCSF) on the clinical and biochemical outcome of type 3 biliary atresia post kasai.

Eligibility

Min Age: 20 DaysMax Age: 1 Year

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Granulocyte Colony-Stimulating Factor for people with biliary atresia and granulocyte colony-stimulating factor. The study is currently recruiting participants at 1 location. People eligible for this study include aged 20 Days to 1 Year.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGGranulocyte Colony-Stimulating Factor

20 patients will receive subcutaneous GCSF at a daily dose of 10ug/kg for 3 consecutive days. It is administered within 3-4 days after the Kasai procedure.

Locations(1)

National Liver Institute

Cairo, Menofia Governorate, Egypt

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06708572

Related Trials

Preventive Effect of Prophylactic Oral Antibiotics Against Cholangitis After Kasai Portoenterostomy

NCT059253091 location

Use of Indocyanine Green (ICG) for the Diagnosis of Biliary Atresia

NCT075130381 location